Search
for

    Research

    5 / 1000+ results
      Pathological Sequelae of Long-Haul COVID

      research Pathological sequelae of long-haul COVID

      353 citations , February 2022 in “Nature Immunology”
      This review explores post-COVID-19 syndromes and the underlying mechanisms, including persistent inflammation, autoimmunity, and possible viral reservoirs, but reports no new clinical results.
      Long COVID Syndrome: An Unfolding Enigma

      research Long COVID syndrome: An unfolding enigma

      17 citations , September 2024 in “The Indian Journal of Medical Research”
      This source explores long COVID syndrome and identifies risk factors like older age, female gender, and comorbidities such as diabetes. It mentions potential diagnostic biomarkers, highlights ongoing clinical trials, and emphasizes the importance of vaccines and rehabilitation in managing long COVID.

      research Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workers

      14 citations , June 2023 in “Journal of Infection and Public Health”
      This study observed a low rate of long-COVID lasting more than three months among mostly vaccinated healthcare workers during the Omicron wave, suggesting that further research is needed to assess the impact of different vaccines on long-COVID-19 in this group.

    Community Join

    5 / 1000+ results

      community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?

      in Chat  45 upvotes 8 months ago
      Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

      community How long are Pelage going to milk the phase 2a results of PP405?

       21 upvotes 7 months ago
      PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

      community Kintor long term safety phase 3

      in Research/Science  66 upvotes 1 year ago
      Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

    Learn

    5 / 801 results